Mechanistic Target of Rapamycin (mTOR) Inhibitors
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/164_2021_553
Reference85 articles.
1. Andrassy J et al (2012) Is cytomegalovirus prophylaxis dispensable in patients receiving an MTOR inhibitor–based immunosuppression? A systematic review and meta-analysis. Transp J 94(12):1208–1217. https://doi.org/10.1097/tp.0b013e3182708e56
2. André F et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580–591. https://doi.org/10.1016/s1470-2045(14)70138-x
3. Arora S, Andreassen AK, Karason K et al (2018) Effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo heart transplant recipients. Circ Heart Fail 11(9):e004050
4. Asleh R et al (2017) Sirolimus-based immunosuppression mitigates progression of cardiac allograft vasculopathy and improves cardiac outcomes after heart transplantation: a single center 15-year follow-up study. J Am Coll Cardiol 69(11):697. https://doi.org/10.1016/s0735-1097(17)34086-x
5. Asleh R, Briasoulis A, Kremers WK et al (2018) Long-term sirolimus for primary immunosuppression in heart transplant recipients. J Am Coll Cardiol 71:636–650
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Benefits and Challenges of Drug-Coated Balloons in Peripheral Artery Disease: From Molecular Mechanisms to Clinical Practice;International Journal of Molecular Sciences;2024-08-11
2. Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity;Stem Cell Research & Therapy;2024-07-02
3. The Cytoprotective and Cytotoxic Functions of Autophagy in Response to mTOR Inhibitors;Frontiers in Bioscience-Landmark;2024-06-24
4. Paediatric hydrocephalus;Nature Reviews Disease Primers;2024-05-16
5. Construction of an immune‐related prognostic model and potential drugs screening for esophageal cancer based on bioinformatics analyses and network pharmacology;Immunity, Inflammation and Disease;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3